Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi‐institutional randomized controlled trial

2020 ◽  
Author(s):  
Junichi Kitagawa ◽  
Ryo Kobayashi ◽  
Yasuyuki Nagata ◽  
Senji Kasahara ◽  
Takaaki Ono ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Oral Mucositis ◽  
Controlled Trial ◽  
Hematopoietic Stem ◽  
Randomized Controlled

scholarly journals Azithromycin Oral Suspension in Prevention and Management of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial

2021 ◽  
Author(s):  
Sayeh Parkhideh ◽  
Mohadeseh Zeraatkar ◽  
Omid Moradi ◽  
Abbas Hajifathali ◽  
Mahshid Mehdizadeh ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Oral Mucositis ◽  
Controlled Trial ◽  
Intervention Group ◽  
Hematopoietic Stem ◽  
Randomized Controlled

Abstract Objectives: This study aimed to investigate the effects of Azithromycin suspension on oral mucositis in patients undergoing hematopoietic stem cell transplantation (HSCT)Methods and material: The study was designed as a single-blind randomized controlled trial in Taleghani medical center affiliated to Shahid Beheshti University of Medical Sciences Tehran Iran. Patients undergoing HSCT were randomly assigned to intervention or control groups. Azithromycin suspension was administered twice daily for gargling for 30 seconds and swallow, on the first day of chemotherapy for patients in the intervention group. Graded Oral Mucositis (OM) occurrence based on National Cancer Institute Common Toxicity Criteria (NCI-CTC) scale (grade 0 to 5) considered as the main outcome and the Numerical Rating Scale (NRS:0-10) measured the severity of OM symptoms.Results: In a duration of fifteen months, 88 patients were randomly assigned and finally 70 patients were evaluable for study outcomes (randomized 1:1 to azithromycin versus no-azithromycin). The incidence and duration of the mucositis significantly improved in the intervention group compared to the control. Azithromycin use was consistent with a lower rate of dryness (P<0.001), dysphagia (P<0.001), and loss of sense of taste (P<0.001). Also, in the intervention group, lower intensity of pain due to mucositis (P=0.01) and lower duration of mucositis were observed (p=0.045). No significant adverse drug reaction was observed in patients receiving azithromycin. Conclusion: Based on the result from this study Azithromycin suspension is an effective option in the prevention and treatment of chemotherapy-induced OM. Further study is needed to assess the effect of azithromycin and comparison with other therapeutic options.

Sign in / Sign up

Export Citation Format

Share Document